# Cochrane Library

# Trusted evidence.

# Informed decisions.

# Better health.

# Cochrane Database of Systematic Reviews

# NCT03804931 (Continued)

# Exclusion criteria

- Antibiotic use within 7 days
- High risk of toxic megacolon
- Colon cancer or neoplasia
- Other severe diseases (cardiovascular, respiratory, gastrointestinal, kidney)

# Interventions

# Experimental arm

- 200 mL prepared fecal suspension from healthy donors, injected into intestine; 2 treatments + mesalazine or prednisone (or both)

# Control arm

- Saline infusion + mesalazine or prednisone (or both)

# Outcomes

# Primary outcomes

- Clinical remission (Total Mayo score < 2 and no subscore > 1) at week 12
- Clinical improvement (Total Mayo score decreased > 3) at week 12

# Secondary outcomes

- Change in intestinal microbiota composition after FMT vs original microbiota and donor microbiota at week 12

# Starting date

# Contact information

# Notes

# NCT03998488

# Study name

# Methods

Single-center RCT conducted in the US

# Participants

# Inclusion criteria

- People age ≥ 18 years with intact descending colon
- Documented prior history of mild-to-moderate UC
- Endoscopically confirmed active UC ≥ 15 cm at week 0 screening via colonoscopy (Total Mayo score 4–10 with Endoscopic subscore ≥ 1)
- If on steroid or biologic therapy, stable dose for 4 weeks prior to screening, maintained throughout trial
- Discontinuation of anti-rCDI antibiotics (e.g. vancomycin, fidaxomicin) 48 hours prior to FMT delivery

# Exclusion criteria

- Biopsy-confirmed CD
- Severe UC (Total Mayo score > 10)
- Clinical complications requiring emergent management, such as stricture, bowel obstruction, perforation, abscess, or a combination of these
- History of FMT
- PSC

# Fecal transplantation for treatment of inflammatory bowel disease (Review)

Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.